Cite
HARVARD Citation
Douglas, G. et al. (2017). Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea. Leukemia & lymphoma. 58 (1), pp. 89-95. [Online].